Cantor raises PTC Therapeutics stock price target on Fabry deal
Cantor Fitzgerald raised its price target for PTC Therapeutics (NASDAQ:PTCT) to $137 from $130, citing the company's acquisition of ST-920, a gene therapy for Fabry disease. The new target suggests over 100% upside from the current stock price. PTC reported strong Q2 2026 earnings, beating expectations and raising its full-year revenue outlook. The company expects to be profitable this year with an EPS forecast of $2.00.
How this was made
The 30-second read
Why it matters
The deal expands PTCT's pipeline into Fabry disease, potentially boosting future revenues and justifying a higher valuation.
Market read
Analyst target raise following a significant acquisition may drive short‑term buying interest in PTCT.
What to watch
Regulatory contingent payments and integration risk are not reflected in the new target.
Background
PTCT announced closure of its ST-920 acquisition on Sep 21 and reported Q2 earnings earlier; Cantor raised its price target the next day.
Ticker impact
Cantor raised PTCT price target to $137 after the company completed its acquisition of ST-920 gene therapy for Fabry disease.
Potential price rally toward new target if market digests acquisition benefits.
Deal adds late‑stage asset and analyst sees significant upside, prompting a target increase.
Market effects
Biotech sector may see renewed interest in gene‑therapy acquisitions.
US biotech investors could re‑price similar late‑stage deals.
Adds to broader trend of consolidation in rare‑disease therapeutics.
Counterpoint
The acquisition may strain cash flow and the target could be overly optimistic.
Key entities
- CompanyPTC Therapeutics
Biotech firm acquiring ST-920.
- AnalystCantor Fitzgerald
Raised price target and rating for PTCT.
